We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sorrento Therapeutics Inc
An SI Board Since January 2010
Posts SubjectMarks Bans Symbol
171 14 0 SRNE
Emcee:  alenor Type:  Unmoderated
Remember QBSW? Quikbyte did a reverse merger and is now:
"Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease."
Recent news starts like this:
"SAN DIEGO, Jan 11, 2010 /PRNewswire via COMTEX News Network/ --
Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA). ..."
***** MOST RECENT *****
SAN DIEGO, Aug. 1, 2013 /PRNewswire via COMTEX/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that it has filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split of its common stock, effective on July 30, 2013. The proposal to effect a reverse stock split was approved by the Company`s stockholders at its Special Meeting of Stockholders held on April 26, 2013, and the specific 1-for-25 ratio was subsequently approved by the Company`s Board of Directors. At the effective time of the reverse stock split, every twenty five shares of the Company`s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split will affect all shares of the Company`s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company`s equity incentive plans. In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split. The Company`s common stock will begin trading on the OTC QB on a split-adjusted basis when the market opens on Thursday, August 1, 2013. The new CUSIP number for the Company`s common stock following the reverse stock split is 83587F 202.

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
171Sorrento Therapeutics awarded antibodies patents Oct. 13, 2020 3:29 PM ET|About:Julius Wong-October 13
170Sorrento up 7% on discovery of small molecule coronavirus inhibitor Sorrento Julius Wong-October 7
169Sorrento gets FDA nod for early-stage COVID-19 antibody trial Sep. 17, 2020 12:3Julius Wong-September 17
168Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-NanoparticJulius Wong-September 14
167Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects HJulius Wong-August 28
166Video of Zev Willams Inventor of Columbia co-19 test on youtube youtube.comJulius Wong-August 21
165Sorrento picks up color-changing COVID-19 saliva test built by Columbia UniversiJulius Wong-August 21
164SRNE Pipeline sorrentotherapeutics.comJulius Wong-August 20
163Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop PipelineJulius Wong-August 20
162Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High PotJulius Wong-August 19
161Sorrento Therapeutics -10.4% after CFO's ouster Aug. 18, 2020 6:30 PM ET|AboJulius Wong-August 18
160Sorrento Therapeutics Stock: Ignore Hindenburg insiderfinancial.comJulius Wong1August 14
159Sorrento to Take Action Against Hindenburg Research for Statements Believed InteJulius Wong-August 13
158COVI-TRACK Registration accessdata.fda.govJulius Wong-August 12
157Hindenburg Research a skeptic of Sorrento's COVID spit test seekingalpha.coJulius Wong1August 11
156SEC FORM 8-K Wong1August 10
1552 Top Coronavirus Stocks with Massive Upside Potential NVAX, SRNE finance.yahooJulius Wong-August 9
154Sorrento Therapeutics Month in Focus August 2020 biotechboom.orgJulius Wong-August 9
153upcoming COVID-19 Mab DNA Plasmid delivery approach by Sorrento/ Smart Pharm ThJulius Wong-August 7
152Celularity announces the activation of first California Clinical Trial Site follJulius Wong-August 5
151Jim Cramer: I can't take how stupidly bullish this market can be Aug 4, 2020Julius Wong1August 5
150Sorrento Therapeutics on the company's Covid-19 saliva test CNBC Aug 4, 2020Julius Wong-August 5
149Analysts’ Top Healthcare Picks: Infinity Pharma (INFI), Sorrento Therapeutics (SJulius Wong-July 31
148Sorrento Therapeutics: Two Month News Recap biotechboom.orgJulius Wong1July 31
147Sorrento Announces License From Columbia University For Rapid On-Site Detection Julius Wong1July 29
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):